RYZ-101-201 Phase 1b/2 open-label trial of Ac225 Dotatate (RYZ101) alone and with pembrolizumab in subjects with ER+, HER2-, unrecsectable or metastatic breast cancer expressing SSTRs and progressed after antibody-drug conjugates and/or chemotherapy.



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*